The Sudden Closure of Northwestern University’s Stem Cell Therapy Clinic Raises Questions That Remain Unanswered

According to a recent article in The Scientist, Northwestern Medicine’s successful autoimmune and immunotherapy program is winding down and will be closed by the end of the year. The program,…

Continue Reading The Sudden Closure of Northwestern University’s Stem Cell Therapy Clinic Raises Questions That Remain Unanswered
Enrollment Finishes Early for a Late Stage Hemophilia B Gene Therapy Clinical Trial
lisichik / Pixabay

Enrollment Finishes Early for a Late Stage Hemophilia B Gene Therapy Clinical Trial

According to a story from Hemophilia News Today, the drug developer uniQure has completed its goals for patient enrollment ahead of time for is phase 3 clinical trial. This clinical…

Continue Reading Enrollment Finishes Early for a Late Stage Hemophilia B Gene Therapy Clinical Trial
Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis
rawpixel / Pixabay

Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis

According to a story from BioPortfolio, Alexion Pharmaceuticals, Inc. and Eidos Therapeutics, Inc., have recently struck an agreement related to the development and marketing of an experimental treatment for hATTR…

Continue Reading Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis

Patients in Mayo Clinic’s RIGHT Study Carried One or More Genetic Variants That May Affect Their Response to Medication

  Pharmacogenomics plays an important role in predicting whether patients will benefit from certain medications or if the medication will cause serious side effects. The process involves the way in…

Continue Reading Patients in Mayo Clinic’s RIGHT Study Carried One or More Genetic Variants That May Affect Their Response to Medication
Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
TeroVesalainen / Pixabay

Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease

According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…

Continue Reading Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
Close Menu